Baricitinib for neurological Kohlmeier-Degos disease
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests if the drug baricitinib can help people with Degos disease that has affected their brain or nerves. It aims to control inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with systemic Degos disease with brain or nerve problems
- You can take pills by mouth and follow the treatment plan
- Women who can get pregnant must use effective birth control during the study and for 30 days after
- You are willing and able to give written permission to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
This trial tests a pill called baricitinib to see if it helps people recover from lung injury after a brain bleed. It is for patients who need a breathing machine due to ARDS that started within a week of the bleed.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
Hear when a new Kohlmeier-Degos Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.